Clinical Trial Supply Planning: What Sponsors Must Get Right Before First Patient In

A clinical trial cannot move forward without a reliable investigational product supply. If the right drug is not in the right place, at the right time, and in the right quantity, even the most scientifically sound study can stall. Missed shipments delay dosing, inaccurate forecasts create waste or stockouts, and small operational gaps can cascade into costly protocol deviations.

Clinical supply managers operate at the center of this complexity. They balance uncertainty, global logistics, regulatory requirements, and evolving study designs while ensuring investigational product is always available when patients need it.

Whether supporting a first-in-human Phase 1 study or a global Phase 3 program, successful clinical trial supply planning depends on several foundational practices. The most effective supply strategies combine strong forecasting, cross-functional coordination, thoughtful system design, and resilient distribution planning.

Below are key operational practices clinical supply teams rely on to keep trials running.

1. Communicate Constantly

Cross-functional alignment prevents surprises and protects supply continuity.

Clinical supply decisions are influenced by multiple stakeholders including Clinical Operations, CMC, Regulatory Affairs, Quality, and study management teams. Without structured communication, protocol amendments, enrollment changes, or packaging adjustments can disrupt supply planning before teams recognize the impact.

Strong clinical supply teams establish recurring cross-functional communication and maintain visibility into operational risks throughout the study lifecycle.

Do

• Conduct recurring cross-functional meetings with Clinical Operations, CMC, Regulatory, Quality and Supply teams
•  Maintain a transparent risk log with mitigation plans
• Define clear ownership for decisions that impact supply, including protocol amendments and packaging changes
• Communicate proactively with investigational sites about resupply timelines and potential delays

Don’t

• Wait until changes occur to evaluate supply impact
• Allow supply planning to happen in functional silos
•  Operate without clear accountability for supply decisions

2. Build a Flexible, Data-Driven Forecast

A strong clinical supply strategy begins with a forecast that reflects protocol realities and adapts as trials evolve.

Clinical supply forecasting should be built around protocol-driven assumptions such as screen failure rates, dropout expectations, visit schedules, and dosing intervals. However, even the most thoughtful forecast must adapt as enrollment patterns and site activation timelines change.

Effective supply teams treat forecasting as a living process supported by scenario modeling and regular updates based on real enrollment data.

Do

• Build forecasts using protocol-driven assumptions including screen failure, dropout rates, and visit windows
•  Use scenario-based modeling to evaluate enrollment variability and geographic expansion
•  Refresh forecasts regularly based on actual enrollment data and site activations

Don’t

• Rely on static assumptions that never change
• Overestimate enrollment rates which can drive unnecessary manufacturing and waste
• Underestimate resupply demand at high-enrolling sites

3. Align Manufacturing and Packaging Strategy

Upstream readiness prevents downstream delays. Clinical supply timelines must align with manufacturing campaigns, packaging readiness, and labeling requirements to ensure investigational product is available when needed. Misalignment between these activities can quickly create supply constraints that delay enrollment.

Early coordination between supply teams, manufacturing partners, and CMC groups helps maintain study timelines and prevents avoidable disruptions.

Do

• Align manufacturing schedules with projected enrollment milestones
• Plan global labeling and translation timelines early
• Use labeling strategies such as booklet labels to support multi-country flexibility
• Design packaging that supports patient usability and dosing compliance

Don’t

• Introduce late formulation or packaging changes that impact production timelines
• Underestimate lead times for label translation, comparator sourcing, or QA release

4. Design Smart IRT Supply Logic

IRT systems control how investigational product moves through a clinical trial. Well-designed supply logic protects inventory balance, maintains blinding, and ensures sites receive the right product when needed.

Poorly designed IRT supply parameters can lead to stock imbalances, unnecessary resupply shipments, or drug shortages at active sites. Clinical supply teams should engage early in IRT design to ensure system logic reflects real operational conditions.

Do

• Engage supply teams early during IRT system design
• Define resupply triggers, buffer stock levels, and depot-to-site supply logic clearly
• Incorporate dose tracking and accountability mechanisms
• Ensure system logic protects study blinding where required

Don’t

• Over-resupply sites which can drive unnecessary waste
• Delay system updates when protocol amendments change supply needs

5. Optimize Depot and Distribution Strategy

Where inventory sits and how quickly it can move plays a critical role in supply reliability.

Depot selection should consider regulatory timelines, import and export processes, cold chain capability, and courier performance. Choosing depots based solely on cost can introduce unnecessary operational risk.

Strong distribution planning ensures inventory visibility, reliable shipping lanes, and sufficient buffer stock to support enrollment variability.

Do

• Select depots based on regulatory capability, geographic risk, and courier performance
• Maintain real-time inventory visibility across depots and sites
• Establish validated cold chain shipping lanes when temperature control is required
• Maintain adequate depot buffer stock during high enrollment periods

Don’t

• Choose depots based solely on cost
• Underestimate cold chain complexity or courier variability
• Allow depot inventory levels to fall too low during enrollment surges

Why Clinical Trial Supply Planning Matters More Than Ever

Clinical trials are becoming increasingly complex. Global enrollment, adaptive protocols, decentralized models, and evolving regulatory expectations all place greater pressure on supply operations. Sponsors who treat clinical supply planning as a strategic discipline rather than an operational afterthought are far better positioned to maintain enrollment momentum, protect patient safety, and avoid costly delays.

Strong supply planning enables trials to adapt as conditions change while ensuring investigational product remains consistently available across every region and site.

How CSC Supports Clinical Trial Supply Success

Clinical Supply Consulting partners with sponsors to design and manage clinical supply strategies that support enrollment, reduce operational risk, and keep trials moving.

Our consultants bring deep experience across global clinical programs and support sponsors with:

• Clinical supply forecasting and scenario modeling
• End-to-end supply strategy development
• IRT design and oversight
• Vendor selection and management
• Rapid issue resolution and trial rescue support
• Clinical systems UAT

If you are preparing for an upcoming clinical trial and want to ensure your supply strategy is built for real-world execution, connect with a CSC expert to learn how we can help strengthen your clinical supply operations.